Ionis, Roche's sefaxersen cuts proteinuria 43.1% versus placebo in Phase 3 IgAN trial

• Ionis Pharmaceuticals partner Roche reported Phase 3 results showing sefaxersen significantly reduced proteinuria versus placebo in adults with IgA nephropathy.
• Results were presented at the American Society of Nephrology Kidney Week 2026; no new safety signals emerged.
• The ongoing trial will assess longer-term kidney function; Roche plans to share data with health authorities.
• Licensed to Roche, sefaxersen could generate regulatory and sales milestone payments for Ionis, alongside tiered royalties on net sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610231337BIZWIRE_USPR_____20261022_BW913461) on October 23, 2026, and is solely responsible for the information contained therein.